ru en
MEDICAL
RESEARCH AND PRODUCTION
COMPLEX
+7 495 327-8630
Development and
manufacturing of
metabolic drugs
Effective. Innovative. Scientific.
Check
your symptoms
Biotredin®

The universal regulator of psychoemotional state. It stimulates the inhibitory processes; enhances a mental capacity due to attention focusing; gives an opportunity to get rid of morbid attraction. Specialists name it the “medicine of achieving the goals”.

Marketing authorization number Р № 003744/01 dated 16.11.2004. Russian Federation patent № 2097034

Glycine

The perfect anti-stress drug for the entire family. It decreases a tension, enhance mood, increases working capacity, normalizes the sleep, decrease toxic effect in case of by poisoning. It is indicated for the treatment of arterial hypertension, vegetative-vascular dystonia, residual effects after brain injuries, acute ischemic stroke.

Marketing authorization number Р № ЛСР -001431/07 dated 09.07.2007. Russian Federation patent № 2097034, Russian Federation patent № 2082398

Limontar®

The first medicine for a newborn. The drug enhances the energy production in cells in ATP form, has anti-hypoxic and antioxidant properties, improves the pregnancy course and outcome, reduces alcohol intoxication, stimulates gastric acid secretion and increases the appetite.

Marketing authorization number Р № 000176/01 dated 06.06.2008. Russian Federation patent № 2039556.

Eltacin®

The drug with antioxidant properties; it has ability to normalize the oxidation-reduction processes and oxygen utilization in tissues. It also increases myocardial contractility and physical tolerance, improves the quality of life of patients with heart failure.

Marketing authorization number № ЛС-000499. Russian Federation patent № 2096034.

Trade name
Biotredin®
International
nonproprietary name
Biotredin
Marketing authorization number
Р N003744/01

Pharmacological group: Drug for treatment of alcoholism

ATC code [А11JC]

Pharmacological properties

    Biotredin® acts as a tissue metabolic regulator, enhances mental capacity, has a therapeutic effect on alcohol withdrawal syndrome, decreases attraction to alcohol. L-threonine in the presence of pyridoxine (vitamin B6) decomposes into glycine amino acid and acetaldehyde (acetic acid), which simultaneously stimulate inhibitory processes, oxidation-reduction reactions, cell respiration processes and ATP synthesis; as a result, Biotredin® is able to:

  • decrease psycho-emotional tension;
  • enhance short-term and long-term memory;
  • enhance mental efficiency;
  • enhance mood;
  • increase and normalize endogenous acetaldehyde level and so decrease alcohol abstinence syndrome and attraction to alcohol. Effect of Biotredin® occurs in 10-20 min after the sublingual administration.

Pharmacokinetics

L-threonine and pyridoxine are completely metabolized into water and carbon dioxide. Accumulation in the organism doesn’t occur.

Indications

Biotredin® is prescribed to children, teenagers and adults with decrease of mental efficiency and ability to concentrate. Biotredin® is indicated in persons with alcohol abuse, patients with chronic alcoholism in cases of actualization of chronic alcoholism combined with affective (irritability, low mood, internal discomfort), sensory (hunger) and ideational (thoughts about alcohol) disorders, for treatment of alcohol abstinence syndrome, and also for maintenance of remission.

Trade name
Glycine
International
nonproprietary name
Glycine
(aminoacetic acid)
Marketing authorization number
P № ЛСР-001431/07

Pharmacological group: Metabolic drug

ATC code N06BX

Pharmacological properties

    Glycine acts as a metabolic regulator, normalizes and activates processes of defensive inhibition in central nervous system (CNS), decreases psycho-emotional tension, enhances mental capacity. Glycine has a glycine- and GABA-ergic effect, alpha1-adrenoblocking, anti-oxidant and anti-toxic effects; it regulates activity of glutamate receptors (NMDA); as a result, Glycine is able to:

  • decrease psycho-emotional tension, aggression, proneness to conflict, enhance social integration;
  • enhance mood;
  • ease the difficulties in falling asleep and normalize the sleep;
  • enhance mental efficiency;
  • decrease vegetative-vascular disorders (as well in the period of menopause);
  • decrease severity of cerebral disorders induced by ischemic stroke and traumatic brain injury;
  • decrease the toxic effect of alcohol and other drugs which depress CNS functions.

Pharmacokinetics

Glycine easily penetrates into most biological fluids and tissues, including the brain; is metabolized into water and carbon dioxide, its accumulation in tissues does not occur.

Indications

  • reduced mental efficiency;
  • stress situations – psycho-emotional tension (during exams, conflicts and other similar situations;
  • deviant behavior of children and teenagers;
  • various functional and organic diseases of nervous system which are accompanied by nervousness, emotional instability, decreasing of mental efficiency and sleep disorders.
Trade name
Limontar®
International
nonproprietary name
Citric acid + Succinic acid.
Marketing authorization number
000176/01-060608

Pharmacological group: Metabolic drug

ATC code А15

Pharmacological properties

    Limontar® acts as a tissue metabolic regulator, enhances the oxidation-reduction processes and the production of ATP; as a result, it has antioxidant and anti-hypoxic properties and is able to:

  • activate functions of organs and tissues;
  • increase reactivity of the organism;
  • enhance mental and physical efficiency;
  • enhance pregnancy course and fetal development;
  • increase secretion of the gastric acid, production of hydrochloric acid, enhance an appetite;
  • decrease the toxic effect of alcohol;

Pharmacokinetics

Citric and succinic acid are completely metabolized into water and carbon dioxide; their accumulation in the organism doesn’t occur.

Indications

Limontar® is used: as a drug for increasing of non-specific reactivity of the organism of pregnant women, enhancing their adaptation and compensation abilities for prevention of hypoxia complications, fetus hypotrophy, and pregnancy loss. It is used for prevention of alcohol intoxication; in treatment of acute alcohol intoxication of mild or medium severity for decreasing of the toxic effect of alcohol and post-toxic disorders; in complex therapy of dipsomania in patients with alcohol addiction; for complex treatment of asthenovegetative disorder (common weakness, decreasing of efficiency, loss of appetite) at a periods of alcohol abstinence syndrome. Limontar® is also used as a test-breakfast in analysis of secretory and acid-forming gastric functions (diagnostic utility of Limontar® and that of histamine are equal).

Trade Name
Eltacin®
International
nonproprietary name
Eltacin
Marketing authorization number
P № ЛС-000499

Pharmacological group: Antioxidant drug

ATC code C01EX

Pharmacological properties

    Eltacin® contains the mix of nonessential amino acids: Glycine, L-glutamic acid and L-cystine. Eltacin® acts as a metabolic regulator: increases the intracellular level of glutathione and glutathione-dependent enzymes, normalizes oxidation-reduction processes and oxygen utilization in tissues; as a result, the drug is able to:

  • have an antioxidant and anti-hypoxic effect;
  • enhance the myocardial contractility;
  • enhance physical tolerance, enhance life quality of patients with heart failure;
  • the drug is non-toxic; it hasn’t the local irritating effect.

Indications

The drug is indicated for treatment of the functional class I-III chronic heart failure (on the background of a basic therapy).

Hotline - 8 800 100 32-22
Ask
an
expert
Send
Your message has been succesfully sent!